Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5684 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer
NCT06104449Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Merck & Co. Primary endpoints: Dose-limiting Toxicity up to 28 days, Adverse Events and 1 more. Started Nov 2023; status: completed.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06104449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104449.